180 related articles for article (PubMed ID: 11074064)
21. Ascites sarcoma 180, a tumor associated with hypercalcemia, secretes potent bone-resorbing factors including transforming growth factor alpha, interleukin-1 alpha and interleukin-6.
Suzuki K; Yamada S
Bone Miner; 1994 Dec; 27(3):219-33. PubMed ID: 7696888
[TBL] [Abstract][Full Text] [Related]
22. A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1beta, TNF-alpha, PTH, PTHrP, and 1, 25(OH)2D3.
Morony S; Capparelli C; Lee R; Shimamoto G; Boone T; Lacey DL; Dunstan CR
J Bone Miner Res; 1999 Sep; 14(9):1478-85. PubMed ID: 10469275
[TBL] [Abstract][Full Text] [Related]
23. Serum markers of bone metabolism in multiple myeloma: prognostic value of the carboxy-terminal telopeptide of type I collagen (ICTP). Nordic Myeloma Study Group (NMSG).
Abildgaard N; Bentzen SM; Nielsen JL; Heickendorff L
Br J Haematol; 1997 Jan; 96(1):103-10. PubMed ID: 9012695
[TBL] [Abstract][Full Text] [Related]
24. Intestinal calcium absorption and bone metabolism in young adult men with childhood-onset growth hormone deficiency.
de Boer H; Blok GJ; Popp-Snijders C; Sips A; Lips P; van der Veen E
J Bone Miner Res; 1998 Feb; 13(2):245-52. PubMed ID: 9495517
[TBL] [Abstract][Full Text] [Related]
25. Comparison of two immunoradiometric assays for parathyroid hormone-related protein in the evaluation of cancer patients with and without hypercalcemia.
de Miguel F; Motellón JL; Hurtado J; Jiménez FJ; Esbrit P
Clin Chim Acta; 1998 Oct; 277(2):171-80. PubMed ID: 9853700
[TBL] [Abstract][Full Text] [Related]
26. Humoral hypercalcemia of malignancy with elevated plasma PTHrP, TNF alpha and IL-6 in cutaneous squamous cell carcinoma.
Mori H; Aoki K; Katayama I; Nishioka K; Umeda T
J Dermatol; 1996 Jul; 23(7):460-2. PubMed ID: 8772024
[TBL] [Abstract][Full Text] [Related]
27. Collagen-related markers of bone turnover reflect the severity of liver fibrosis in patients with primary biliary cirrhosis.
Guañabens N; Parés A; Alvarez L; Martínez de Osaba MJ; Monegal A; Peris P; Ballesta AM; Rodés J
J Bone Miner Res; 1998 Apr; 13(4):731-8. PubMed ID: 9580479
[TBL] [Abstract][Full Text] [Related]
28. The relationship of fetal serum markers of bone metabolism to gestational age.
Ogueh O; Khastgir G; Studd J; Jones J; Alaghband-Zadeh J; Johnson MR
Early Hum Dev; 1998 May; 51(2):109-12. PubMed ID: 9605463
[TBL] [Abstract][Full Text] [Related]
29. Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer.
Kylmälä T; Tammela TL; Risteli L; Risteli J; Kontturi M; Elomaa I
Br J Cancer; 1995 May; 71(5):1061-4. PubMed ID: 7734300
[TBL] [Abstract][Full Text] [Related]
30. Biochemical evaluation of bone turnover in cancer patients with bone metastases: relationship with radiograph appearances and disease extension.
Berruti A; Piovesan A; Torta M; Raucci CA; Gorzegno G; Paccotti P; Dogliotti L; Angeli A
Br J Cancer; 1996 Jun; 73(12):1581-7. PubMed ID: 8664134
[TBL] [Abstract][Full Text] [Related]
31. [Serum concentration of pyridinoline cross-linked carboxy-terminal telopeptide of type-I collagen (ICTP) and carboxyterminal propeptide of human type I procollagen (PICP) in the diagnosis of bone metastases].
Koizumi M; Yamada Y; Takiguchi T; Suzuki C; Akashi T; Nomura E; Yamashita T; Ogata E
Kaku Igaku; 1996 Jan; 33(1):77-84. PubMed ID: 8819718
[TBL] [Abstract][Full Text] [Related]
32. Circulating parathyroid hormone-related protein (109-141) in malignancy-associated hypercalcemia.
Nagasaki K; Otsubo K; Kajimura N; Tanaka R; Watanabe H; Tachimori Y; Kato H; Yamaguchi H; Saito D; Watanabe T; Adachi I; Yamaguchi K
Jpn J Clin Oncol; 1996 Feb; 26(1):6-11. PubMed ID: 8551669
[TBL] [Abstract][Full Text] [Related]
33. Raised plasma concentrations of parathyroid hormone related peptide in hypercalcemic multiple myeloma.
Horiuchi T; Miyachi T; Arai T; Nakamura T; Mori M; Ito H
Horm Metab Res; 1997 Sep; 29(9):469-71. PubMed ID: 9370119
[TBL] [Abstract][Full Text] [Related]
34. Hypercalcemia of malignancy: a study of clinical features and relationships among circulating levels of calcium, parathyroid hormone and parathyroid hormone-related peptide.
Sriussadaporn S; Phoojaroenchanachai M; Ploybutr S; Plengvidhya N; Peerapatdit T; Nitiyanant W; Vannasaeng S; Vichayanrat A
J Med Assoc Thai; 2007 Apr; 90(4):663-71. PubMed ID: 17487119
[TBL] [Abstract][Full Text] [Related]
35. Change of cross-linked telopeptide of type I collagen (ICTP) and other bone resorption markers in patients with bone fragility fractures.
Takahara K; Kamimura M; Hashidate H; Uchiyama S; Nakagawa H
J Orthop Sci; 2007 May; 12(3):219-26. PubMed ID: 17530373
[TBL] [Abstract][Full Text] [Related]
36. Plasma parathyroid hormone related-protein levels in patients with cancer, normocalcemic and hypercalcemic.
Segura Domínguez A; Andrade Olivié MA; Rodríguez Sousa T; Terrón Alvarez ML; Rodríguez Perez D; Alvarez Novoa R; García-Mayor RV
Clin Chim Acta; 1996 Jan; 244(2):163-72. PubMed ID: 8714434
[TBL] [Abstract][Full Text] [Related]
37. Changes of bone markers during long-term intravenous calcitriol therapy in maintenance dialysis patients.
Lee SH; Huang TS; Hsieh SJ
Miner Electrolyte Metab; 1996; 22(4):219-23. PubMed ID: 8807625
[TBL] [Abstract][Full Text] [Related]
38. Parathyroid hormone-related peptide in plasma of patients with hypercalcemia and malignant lesions.
Kao PC; Klee GG; Taylor RL; Heath H
Mayo Clin Proc; 1990 Nov; 65(11):1399-407. PubMed ID: 1700240
[TBL] [Abstract][Full Text] [Related]
39. [Cytokines in bone diseases. Cytokines and malignancy-associated hypercalcemia].
Okazaki R
Clin Calcium; 2010 Oct; 20(10):1497-502. PubMed ID: 20890031
[TBL] [Abstract][Full Text] [Related]
40. Serum carboxy-terminal cross-linked telopeptide of type I collagen reflects bone metastasis in hepatocellular carcinoma.
Ueno T; Hashimoto O; Sugawara H; Ogata R; Kusaba N; Torimura T; Sata M; Tanikawa K
Int J Oncol; 1998 Aug; 13(2):297-303. PubMed ID: 9664125
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
